Pathogenetic insights from the treatment of rheumatoid arthritis
- PMID: 28612747
- DOI: 10.1016/S0140-6736(17)31472-1
Pathogenetic insights from the treatment of rheumatoid arthritis
Abstract
Rheumatoid arthritis is a chronic autoimmune disease that causes progressive articular damage, functional loss, and comorbidity. The development of effective biologics and small-molecule kinase inhibitors in the past two decades has substantially improved clinical outcomes. Just as understanding of pathogenesis has led in large part to the development of drugs, so have mode-of-action studies of these specific immune-targeted agents revealed which immune pathways drive articular inflammation and related comorbidities. Cytokine inhibitors have definitively proven a critical role for tumour necrosis factor α and interleukin 6 in disease pathogenesis and possibly also for granulocyte-macrophage colony-stimulating factor. More recently, clinical trials with Janus kinase (JAK) inhibitors have shown that cytokine receptors that signal through the JAK/STAT signalling pathway are important for disease, informing the pathogenetic function of additional cytokines (such as the interferons). Finally, successful use of costimulatory blockade and B-cell depletion in the clinic has revealed that the adaptive immune response and the downstream events initiated by these cells participate directly in synovial inflammation. Taken together, it becomes apparent that understanding the effects of specific immune interventions can elucidate definitive molecular or cellular nodes that are essential to maintain complex inflammatory networks that subserve diseases like rheumatoid arthritis.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Comment in
-
A platinum age for rheumatology.Lancet. 2017 Jun 10;389(10086):2263. doi: 10.1016/S0140-6736(17)31577-5. Lancet. 2017. PMID: 28612734 No abstract available.
Similar articles
-
Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds.Clin Exp Immunol. 2013 Dec;174(3):356-63. doi: 10.1111/cei.12190. Clin Exp Immunol. 2013. PMID: 23968543 Free PMC article.
-
The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.Clin Exp Rheumatol. 2016 Mar-Apr;34(2):318-28. Epub 2016 Mar 10. Clin Exp Rheumatol. 2016. PMID: 26966791 Review.
-
Cytokine Networks in the Pathogenesis of Rheumatoid Arthritis.Int J Mol Sci. 2021 Oct 10;22(20):10922. doi: 10.3390/ijms222010922. Int J Mol Sci. 2021. PMID: 34681582 Free PMC article. Review.
-
Novel therapeutic targets in rheumatoid arthritis.Trends Pharmacol Sci. 2015 Apr;36(4):189-95. doi: 10.1016/j.tips.2015.02.001. Epub 2015 Feb 27. Trends Pharmacol Sci. 2015. PMID: 25732812 Review.
-
Role of JAK-STAT signaling in the pathogenic behavior of fibroblast-like synoviocytes in rheumatoid arthritis: Effect of the novel JAK inhibitor peficitinib.Eur J Pharmacol. 2020 Sep 5;882:173238. doi: 10.1016/j.ejphar.2020.173238. Epub 2020 Jun 16. Eur J Pharmacol. 2020. PMID: 32561292
Cited by
-
Irisin and Bone in Sickness and in Health: A Narrative Review of the Literature.J Clin Med. 2022 Nov 21;11(22):6863. doi: 10.3390/jcm11226863. J Clin Med. 2022. PMID: 36431340 Free PMC article. Review.
-
Screening of Diagnostic Biomarkers and Immune Infiltration Characteristics Linking Rheumatoid Arthritis and Rosacea Based on Bioinformatics Analysis.J Inflamm Res. 2024 Aug 1;17:5177-5195. doi: 10.2147/JIR.S467760. eCollection 2024. J Inflamm Res. 2024. PMID: 39104909 Free PMC article.
-
Targeting BRD4 to attenuate RANKL-induced osteoclast activation and bone erosion in rheumatoid arthritis.Mol Cell Biochem. 2025 Mar;480(3):1669-1684. doi: 10.1007/s11010-024-05073-2. Epub 2024 Aug 7. Mol Cell Biochem. 2025. PMID: 39110281
-
Photobiomodulation effects in metalloproteinases expression in zymosan-induced arthritis.Lasers Med Sci. 2022 Dec;37(9):3661-3670. doi: 10.1007/s10103-022-03647-4. Epub 2022 Sep 26. Lasers Med Sci. 2022. PMID: 36156751
-
Aliskiren, tadalafil, and cinnamaldehyde alleviate joint destruction biomarkers; MMP-3 and RANKL; in complete Freund's adjuvant arthritis model: Downregulation of IL-6/JAK2/STAT3 signaling pathway.Saudi Pharm J. 2020 Sep;28(9):1101-1111. doi: 10.1016/j.jsps.2020.07.011. Epub 2020 Aug 3. Saudi Pharm J. 2020. PMID: 32922141 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous